caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
Company profile
Ticker
LSTA
Exchange
Website
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Corporate docs
Subsidiaries
Athelos Corporation • Lisata Therapeutics Australia Pty Ltd • Lisata Therapeutics Ireland Limited • Lisata Therapeutics (U.K.) Limited • As of December 31, 2023, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568
LSTA stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
17 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
S-8
Registration of securities for employees
13 Jul 23
8-K
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
11 Jul 23
Transcripts
LSTA
Earnings call transcript
2023 Q3
2 Nov 23
LSTA
Earnings call transcript
2023 Q2
15 Aug 23
LSTA
Earnings call transcript
2023 Q1
9 May 23
LSTA
Earnings call transcript
2022 Q4
30 Mar 23
LSTA
Earnings call transcript
2022 Q3
13 Nov 22
LSTA
Earnings call transcript
2022 Q2
5 Aug 22
LSTA
Earnings call transcript
2022 Q2
4 Aug 22
LSTA
Earnings call transcript
2022 Q1
6 May 22
LSTA
Earnings call transcript
2022 Q1
5 May 22
LSTA
Earnings call transcript
2021 Q4
23 Mar 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.43 mm | 32.43 mm | 32.43 mm | 32.43 mm | 32.43 mm | 32.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.99 mm | 2.19 mm | 1.19 mm | 1.87 mm |
Cash used (since last report) | n/a | n/a | 13.52 mm | 14.86 mm | 8.12 mm | 12.71 mm |
Cash remaining | n/a | n/a | 18.91 mm | 17.57 mm | 24.31 mm | 19.72 mm |
Runway (months of cash) | n/a | n/a | 9.5 | 8.0 | 20.4 | 10.5 |
Institutional ownership, Q2 2023
38.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 5 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.17 bn |
Total shares | 3.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.58 mm | $0.00 |
Intracoastal Capital | 949.61 k | $2.21 mm |
BML Capital Management | 243.84 k | $902.20 mm |
Vanguard | 176.14 k | $651.71 mm |
Renaissance Technologies | 93.32 k | $345.00 k |
BLK Blackrock | 56.81 k | $210.18 mm |
Geode Capital Management | 25.97 k | $96.10 mm |
Citadel Advisors | 17.18 k | $63.56 mm |
Dimensional Fund Advisors | 14.95 k | $55.32 mm |
STT State Street | 14.35 k | $53.09 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jan 24 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 2.99 | 1,026 | 3.07 k | 174,766 |
9 Jan 24 | Azab Mohammad | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 58,680 |
9 Jan 24 | Brown Gregory B | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 49,414 |
9 Jan 24 | Schwalm Cynthia | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 49,201 |
9 Jan 24 | Heidi Henson | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 39,480 |
Press releases
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
23 Apr 24
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
23 Apr 24
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
3 Apr 24